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Leucine is transported into E coli by two osmotic shock-sensitive, high-affinity 
systems (LIV-I and leucine-specific systems) and one membrane bound, low- 
affinity system (LIV-11). Expression of the high-affinity transport systems is 
altered by mutations in IivR and l s t R ,  genes for negatively acting regulatory 
elements, and by mutations in rho, the gene for transcription termination. All 
four genes for high-affinity leucine transport (livJ, livK, ZivH, and l ivC) are 
closely linked and have been cloned on a plasmid vector, pOXl.  Several subcloned 
fragments of this plasmid have been prepared and used in complementation 
and regulation studies. The results of these studies suggest that 2ivJ and livK 
are separated by approximately one kilobase and give a gene order of livJ- 
livK-livH. livJ and livK appear t o  be regulated in an interdependent fashion; 
livK is expressed maximally when the livJ gene is inactivated by mutation or  
deletion. The results support the existence of separate promoters for the livJ 
and livK genes. The effects of mutations in the rho and l ivR genes are additive 
on  one another and therefore appear t o  be involved in independent regulatory 
mechanisms. Mutations in the rho gene affect both the LIV-I and leucine- 
specific transport systems by increasing the expression of livJ and livK, genes 
for the LIV-specific and leucine-specific binding proteins, respectively. 
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Two distinct leucine transport systems are present in E coli K12. A low- 
affinity membrane-bound system (LIV-11) is osmotic shock resistant [l-41 and can 
be observed in membrane vesicle preparations [ 51 . High-affinity transport systems 
involving periplasmic leucine-binding proteins (LIV- and leucine-specific binding 
proteins) are sensitive to osmotic shock treatment [4, 61. System LIV-I transports 
L-leucine, L-isoleucine, L-valine, L-threonine, and L-alanine and is absent from strains 
with mutations in ZivJ, the structural gene for the LIV-binding protein. Mutations in 
livK, the structural gene for the leucine-specific binding protein, affect high-affinity 
leucine-specific transport [7] . In addition, two other loci, 1ivH and livG, are essential 
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for both the high-affinity leucine transport systems [8] . All four genes are clustered 
at minute 74 on the revised E coli linkage map [9] . The LIV-I1 system is weakly 
repressed (2-fold) by high exogenous L-leucine levels, in contrast to the more pro- 
nounced repression 0 10-fold) observed for the high-affinity leucine transport 
systems [ l o ] .  
have been characterized and map at min 20 on the E coli chromosome [ 1 11 . These 
mutations, livR and ZstR, appear to code for negatively acting regulatory elements. 
Mutations in several other gene loci alter the activity of the high-affinity transport 
systems. These mutations include rho [I21 ; hisT, which codes for a tRNA modifying 
enzyme [ 131 ; Zeus, a gene locus coding for leucyl-tRNA synthetase [ 141 ; and reZA, the 
gene coding for guanosine 5’-diphosphate 3’-diphosphate (ppGpp) synthesis [ 151 . These 
results suggest that normal leucine transport regulation involves interaction of charged or 
uncharged leucyl-tRNA and rho with transcription and/or translation initiation. The regula- 
tion of leucine transport appears similar to that found for the regulation of the biosynthetic 
operons for tryptophan, histidine, phenylalanine, and leucine [I 6-1 91 . 
Recently we have cloned the entire genetic complex coding for the four known 
LIV-I transport genes into the plasmid vector pACYC184 [20] . When introduced into a 
wild-type regulatory background, the genes on this hybrid plasmid, pOXl, are subject to 
regulation. In this paper we present the results of regulation studies with the cloned 
leucine transport genes and additional characterization of the effect of rho on this 
regulation. 
Two mutations resulting in reduced regulation of high-affinity leucine transport 
METHODS 
Growth Conditions 
Unless otherwise indicated, all strains were grown in MOPS minimal medium [21] 
with 0.2% glucose, 50 pg/ml thymine, L-arginine, and L-histidine, 10 pg/ml of L-tryptophan, 
and 1 pg/ml of L-tryptophan, and 1 pg/ml pyridoxine. 
Transport and Binding Protein Assays 
assayed by osmotic treatment of cells [6] and subjecting the concentrated shock fluids to 
equilibrium dialysis as described previously [4] . 
Leucine transport was assayed as described previously [ I  I ]  . Binding proteins were 
Restriction Endonuclease Digestion, Preparation, and Ligation of Plasmid D N A  
were purchased from Bethesda Research Labs, Inc. (Bethesda, MD). Plasmid DNA was 
prepared by the cleared lysate procedure of Clewell and Helinski [23] and purified by 
CsCl gradient ultracentrifugation. Plasmid restriction fragments were isolated by electro- 
phoresis on 0.8% agarose gels as described previously [24]. Plasmid POX1 was constructed 
as described [20]. Plasmids p o x 5  [29] and p o x 6  were prepared by restricting pOXl with 
BgZ I1 and Pst I, respectively, isolating and religating the fragment containing the pACYC184 
vector sequence with T4 DNA ligase. Plasmid p o x 7  was prepared by isolating the 2.1 kb 
BgZ I1 fragment from POX1 and cloning it into the Bum HI site of pBR322 as described 
[29] . Plasmid POX13 was similarly prepared by cloning the 4.4 kb Hind 111-Bum HI frag- 
ment of POX1 into pBR322 that had been restricted with Bum HI and Hind 111. 
Endonuclease digestions were performed as described by Boyer et a1 [22]. All enzymes 
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MOPS minimal medium plus 0.01 mCi of [3H] -L-alanine. Shock fluids were prepared in 
0.2 ml of 0.5 mM MgClz as described [6]. Aliquots of shock fluid were electrophoresed 
in 11% native polyacrylamide gels as described by Laemmli [26]. The binding protein bands 
were excised from the gel, oxidized in a Packard Sample Oxidizer, and the tritium recovered 
in scintillation fluid for counting. TCA precipitates were treated similarily, and the levels of 
binding proteins were calculated as the percent of total TCA precipitable counts in the 
binding protein bands. 
Detection of Binding Proteins by Nitrocellulose Blot and Antibody Reaction 
Native gels of shock fluids were prepared as above. The electrophoresed proteins 
were transferred to nitrocellulose paper as described by Towbin et a1 [27] in a Savant 
electrophoretic destainer. The paper was incubated with [ lZs I] -labeled anti-LIV-binding 
protein antibody at 37°C for 4 h in the presence of 3% BSA and 1% calf serum to prevent 
nonspecific adsorption. After excess antibody was washed off with PBS, the nitrocellulose 
paper was dried and autoradiographed. 
Transposon tn5 Insertions 
Transposon tn5 was transferred to the POX1 plasmid by infecting a POX1 plasmid- 
containing strain with a temperature sensitive lambda phage carrying the tn5 transposon. 
Infected cells were plated on Luria broth plates containing kanamycin (20 pg/ml) and 
tetracycline410 pg/ml) and incubated at 37°C. Resistant colonies were scraped off the 
plates and used for plasmid DNA preparation. This plasmid preparation was used to trans- 
form strain AE205 (ZivH livJ). Cells carrying a plasmid with a tn5 insertion were selected 
on kanamycin tetracycline Luria broth plates. Those colonies also resistant to 40 pg/ml 
L-valine (phenotype of LIV-I transport mutant) were selected on minimal media plates 
and then screened for synthesis of LIV-binding protein and high-affinity LIV-I transport. 
Colonies that produced LIV-binding protein but were defective in high-affinity L-leucine 
transport contained plasmids with tn5 insertions in ZivH. Colonies that did not produce 
LIV-binding protein and showed high-affinity uptake of L-leucine but not L-valine con- 
tained plasmids with tn5 insertions in ZivJ. 
Cultures (2 ml) of pOXl-transformed strain AE89 (ZivR+ IsrR+ ZivH) were grown in 
RESULTS 
We have previously reported cloning a 13 kb Eco RI fragment into the plasmid vector 
pACYC184 to form the pOXl plasmid, whlch was shown to complement all 4 known 
classes of high-affinity leucine transport mutations [20] . The leucine-specific binding 
protein gene has been located, and the direction of transcription was determined to be 
from left to right in Figure 1. [29] . 
Structure of the L I V  Transport Region 
To define the arrangement of genes in the LIV-I transport region of the POX1 
plasmid, we prepared several plasmids containing a subset of the pOXl DNA sequence. 
Figure 1 shows the portions of the 13  kb Eco RI fragment contained by each of the sub- 
cloned plasmids. The deleted plasmids p o x 5  and p o x 6  contain the entire pACYC184 
vector sequence; p o x 7  and pOXl3 wereqrepared by cloning the respective restriction 
fragments shown in Figure 1 into the plasmid vector pBR322 [25]. The ability of these 
plasmids to complement previously characterized high-affinity leucine transport mutants 
was determined by transforming the various mutants with each plasmid and measuring 
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Fig. 1. Plasmids derived from POX1 were prepared by deleting a small restriction fragment from 
pOXI and reiigating the remaining linear strand with T4 DNA ligase (pox5  and pOX6) or by prepar- 
ing a defined restriction fragment and subcloning it into a site in pBR322 (Barn HI site for p o x 7  and 
the Barn HI and Hind I11 sites for pOX13). These plasmids contain the sequences indicated by the 
solid lines. ZivJ is the structural gene for the LIV-binding protein; livK is the structural gene for the 
leucine-specific binding protein. Restriction sites are indicated by letters. A, Psf I; B, Bgl 11; C ,  Hind 111; 
D, Barn HI; and E, Hinc 11. 
leucine transport. Where appropriate an increase in the synthesis of the binding proteins 
was detected directly by polyacrylamide gel electrophoresis of shock fluids from trans- 
formed strains. The results of these complementation tests, together with the previously 
published pOXI results [20], are presented in Table I .  We have previously shown by DNA 
sequencing that ZivK, the gene for the leucine-specific binding protein, begins 500 bases to 
the right of the left BgZ I1 site shown in Figure 1 and is transcribed in the rightward 
direction [29]. Since POX13 and not p o x 7  complements a mutation in ZivJ, the gene for 
the LIV-binding protein, we conclude that ZivJ is upstream from the ZivK gene. We have 
confirmed this result by isolating a plasmid derived from POX1 with a transposon tn5 
inserted in the ZivJ gene. This plasmid, POX1 : :tn5ZivJ24, contains a tnS insertion approxi- 
mately 500 bases downstream from the right-hand At I site, as shown in Figure 2.  A ZivJ 
mutant transformed with pOXl: :tn51ivJ24 produced no protein cross-reactive with anti- 
body to the LIV-binding protein. Therefore this tn5 insertion must occur early in the 
ZivJ gene. IZivJ is over 1 kb in length (the molecular weight of the WV-binding protein is 
37,500) and is intact on the p o x 6  plasmid, which is deleted between the Pst I sites. There- 
fore, ZivJ must also be transcribed from left to right, as shown in Figure 1. This position of 
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Fig. 2. TnS insertions were isolated as described in Methods. The insertions were mapped by restriction 
enzyme digestion of inserted plasmids and comparison of the products with the known sites in POX1 
and tn5. pOXl::tnSlivH8 was mapped with restriction enzymes Hind 111, Sal I, and Bgl 11. pOX1::tnS- 
IivJ24 was mapped with restriction enzymes Hind 111, Sal I, and Pst I. 
the ZivJ gene leaves a minimum of one kilobase from its end to the beginning of the livK 
gene, a distance sufficient to code for an additional protein of up to 35,000 daltons. This 
region is represented by X in Figure 1. 
ZivH must lie at least in part to the left of the right BgZ I1 site. A tn5 transposon insertion 
in the ZivH gene of POX1 was isolated which confirms this result. As shown in Figure 2 ,  
POX1 ::tnSZivH8 contains a tn5 insertion approximately 100 bases downstream from the 
left BgZ I1 site. We concludeJhat this region, represented by Y in Figure 1, is most likely 
the livH gene. 
the gene map shown in Figure 1. The ZivJ gene has been located as predicted above. Upstream 
from ZivK is a 500-base AT-rich region that contains numerous nonsense codons in all three 
reading frames and is likely to be a spacer or regulatory region for the ZivK gene. Around 
the right BgZ I1 site we have located a sequence that contains a single reading frame not 
interrupted by nonsense codons. When translated, this sequence codes for a basic cysteine- 
rich protein. We expect the ZivH protein to be both basic and cysteine-rich by analogy to 
the hisP protein described by Ames and co-workers for high-affinity histidine transport in 
S typhimurium [30,31].  A similar basic cysteine-rich coding region has been found in 
region X. These DNA sequences will be published elsewhere when completed. 
Regulation of Plasmid Transport Genes 
We have previously shown that the amplified leucine transport present in POX1 
transformed strains is regulated by the concentration of L-leucine in the medium [20]. To 
determine ifDNA sequences involved in the regulation of both leucine-binding protein 
genes areqresent in POX1 and its derivatives, we have assayed the level of the LIV- and 
leucine-specific binding proteins produced when transformed strains were grown in the 
presence and absence of leucine. The results of these experiments are shown in Table 11. 
A comparison of Table I with the plasmid fragments in Figure 1 also reveals that 
Recently we have obtained preliminary DNA sequence information which confirms 
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TABLE I. Complementation of Known LIV Genes by POX Plasmids 
Plasmid livJa l i v P  livHb livGb 
p o x 1  + i + + 
p o x 5  + - - - 
p o x 6  + + + XC 
p o x 7  - + - 
pOX13 i - 
- 
- - 
aBinding protein gene complementation was assayed by detection of gene products on polyacrylamide 
gels. 
blivH and livG complementation was assayed by leucine transport measurements in plasmid-transformed 
mutant strains. 
cX. not determined. 
TABLE 11. Regulation of Binding Protein Synthesis in Transformed Strains 
Binding protein synthesisa 
LIV LS 
Strain Plasmid No Lleucine +L-leucine No L-leucine +L-leucine 
AE89b - 7.9 3.1 2.8 1.0 
pBR322 5.0 3.1 2.0 0.8 
p o x  1 80 51 3.0 1.0 
p o x 5  14 55 2.0 0.8 
p o x 6  89 47 3.5 1.4 
p o x 7  5.6 3.1 23 15 
pOXl3 86 25 2.7 1.0 
a[3H] -L-alanine counts in binding protein/total[ 3H]  -L-alanine counts in TCA precipitate of osmotic 
shock fluid X 100. See Methods for experimental protocol. 
bStrain AE89 is livR+ lstR+ l ivH- .  
Interestingly, while plasmid-bearing strains show an amplification in the level of LIV- 
binding protein, no concomitant rise in leucine-specific binding protein synthesis is evident. 
Only when the livJgene is defective or absent, as in the p o x 7  plasmid, does the ZivK gene 
show amplified expression. In the p o x 7  plasmid, this amplified expression is still regulated 
by leucine. In all plasmids examined, significant regulation of the respective leucine- 
binding protein synthesis was observed. These results suggest that the relevant regulatory 
sequences are present on  these plasmids. In particular, a regulatory region for livK must 
be present in the 500 bases preceding the beginning of the ZivK gene in pOX7. Similarly, 
a regulatory region for ZivJ must b e  present in the 500 bases preceding the beginning of 
the livJ gene in pOX6. The lowered efficiency of regulation seen in the transformed strains 
may be caused by the amplified regulatory sequences, which could saturate the available 
regulatory components. These results support some degree of interdependent yet separate 
regulation for ZivJ and livK gene expression. 
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TABLE 111. Kinetic Constants for LIV Transport and Leucine-Binding Activities in Binding Protein 
Mutants 
LIV uptakea L-leucine binding activity 
L-leucine L-isoleucine L-valine prnole/mg protein 
Strain Genotype K, Vmax K, Vmax K, V, LIV-BPb LS-BPb 
AE84 IivR 0.6 8.3 0.25 4.3 0.22 4 . 2  660 163 
AE840102 livR livJ 0.8 7.7 NDC ND ND ND 34 315 
AE84084 IivR livK ND ND ND ND ND ND 731 0 
"All strains grown in MOPS minimal medium without leucine and harvested during log phase growth. 
K, is given in pM; Vmax in nM/min per mg dry cell wt. 
bLS-BP (leucine-specific binding protein) activity was determined by equilibrium dialysis of crude 
osmotic shock fluids [ 6 ]  in 2.5 pM [3H] -L-leucine + 200 pM L-isoleucine. LIV-BP activity was calcu- 
lated as activity in 2.5 pM [3H]  -L-leucine minus LS-BP activity. 
CND, not detectable. 
Synthesis of Leucine-Specific Binding Protein 
examine the level of leucine-specific binding protein production in non-transformed strains 
that were defective in ZivJ, the LIV-binding protein gene. As shown in Table 111, the 
uptakes of L-isoleucine and L-valine, substrates for LIV-binding protein-mediated trans- 
port, are not detectable in strain AE840102, which lacks the LIV-binding protein. L- 
Leucine transport, however, is virtually unaffected. That this is due to an increase in 
leucine-specific binding protein synthesis resulting in an increase in leucine-specific trans- 
port is evident from measurements of the level of the binding proteins by equilibrium 
dialysis of crude shock fluids. While the amount of LIV-binding protein is 20-fold less in 
strain AE840102 than that in strain AE84, the leucine-specific binding protein is amplified 
The interdependent regulation of ZivJ and ZivK expression in the plasmids led us to 
2-fold. 
Mutation of ZivK in strain AE84084 results in a slight increase in LIV-binding pro- 
tein activity, which isalso consistent with compensatory regulation of the two binding 
protein genes. The low levels of L-isoleucine and L-valine uptake in strain AE84084 are 
probably due to a polar effect of a Mu insertion in ZivK on the expression of the down- 
stream livH gene. 
Rho-Dependent Regulation Is Independent of livR Regulation 
It is now well established that mutations in the gene for transcription termination, 
rho, cause derepression of high-affinity leucine transport [ 121. This phenotype is similar 
to that produced by the ZivR mutation. We wondered, therefore, whether the two effects 
were part Df the same regulatory mechanism or, alternatively, if the rho effect could still 
be observed in livR strains already derepressed for leucine transport. To answer this ques- 
tion, we prepared strain AE141 (livR iZv::tnlO) by transduction of the livR strain AE84 
with P1 phage carrying a transposon tnlO insertion in iZv. Since the rho gene is 85% linked 
to the iZv locus, we were able to introduce a rho201 mutation into strain AE141 by trans- 
ducing it with a P1 phage grown on a rho201 iZv+ strain (kindly provided by J. Beckwith) 
and then selecting for ilv' colonies. As shown in Table IV, leucine uptake was increased 
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over 400% when rho was present in this strain background. On the basis of this result, it 
is unlikely that rho exerts its effect on leucine transport by altering expression of the EivR 
gene..Thus we conclude that rho-dependent termination is involved in leucine transport 
regulation in a manner independent of ZivR repression. 
Rho Affects the Expression of Both livJ and livK 
port results from a rho-dependent termination in transcription attenuation of LIV-I 
transport gene expresqion [ 121 . It is also possible that derepression of LIV-I genes occurs 
because2 termination upstream from one or more of the genes is relieved by mutations in 
rho. In the latter case, one might expect livK expression to be more sensitive to rho 
mutations than the expression of livJ, since ZivK is clearly the downstream gene. To assess 
this possibility, we assayed binding protein synthesis by preparing crude shock fluids of 
strain X8605 and X8605rho201. The strain X8605 background has previously shown a 
reduced rho effect in contrast to the effect found in our own strains (Table IV). We there- 
fore expected strain X8605 shock fluids to show corresponding reduced binding protein 
levels. These shock fluids were electrophoresed on polyacrylamide gels and transferred to 
nitrocellulose paper as described in Methods. Table V shows the results of these assays. 
We previously suggested that the rho-dependent effect on high-affinity leucine trans- 
TABLE IV. Leucine Transport in fivR rho Double Mutants 
Strain Genotype Up takea 
AE141 livR i1v::tnlO 
AE 141 :P1 (rho201)b livR rho 201 
0.21 
1.23 
aExpressed in nM/min per mg dry cell wt at a L-leucine concentration of 0.1 wM. Cells were grown in 
MOPS minimal medium without leucine. 
bStrain AE141 was transduced with P1 phage grown on strain X8605 rho201 ilv+ and selected for 
iZvf (85% linked to rho). The uptake shown is the average of that obtained for four independent 
isolates showing elevated transport. 
TABLE V. Effect of the rho201 Mutation on the Synthesis of LIV- and Leucine-Specific Binding 
Proteins 
LIV-binding proteina LS binding proteina 









aLIV- and leucine-specific binding protein synthesis was detected by the antibody nitrocellulose blot 
method described in Methods. Synthesis was quantitated by determining the amount of [1251] -antibody 
bound by each band from densitometer tracings of the autoradiographs. I t  is expressed as the percent 
relative to LIV-binding protein synthesized by strain X8605 grown without L-leucine after correcting 
for total protein loaded on the gel. 
bCells were grown in MOPS minimal medium as described in Methods with or without 0.1 mM L-leucine 
(13 pg/ml) and harvested in mid-log phase. 
CND, not detectable. 
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Shock fluid from the rho mutant, strain X8605rho201, contains an elevated concentration 
of LIV-binding protein relative to shock fluid from the wild-type strain X8605. The 
leucine-specific binding protein was not detected in shock fluid from strain X8605 but was 
clearly present in shock fluid from strain X8605rho201. Synthesis of neither binding 
protein was sensitive to regulation by external L-leucine when the rho201 lesion was 
present. These results clearly demonstrate that the expression of both binding protein 
genes is sensitive to a defective rho termination factor. 
DI SCUSSl ON 
Previous work in several laboratories has led to the general observation that the level 
of high-affinity transport can be correlated with the concentration of specific periplasmic 
binding proteins for a given transport system [ lo]  . The regulation of synthesis of the LIV- 
and leucine-specific binding proteins is a prime determinant, therefore, in controlling the 
level of high-affinity leucine transport in E coli. 
In this paper wehave shown that ZivJ and ZivK, genes for the LIV- and leucine- 
specific binding proteins, respectively, are separated by approximately 1 kb and are capable 
of independent expression and regulation. Both genes are transcribed in the same direction. 
It has been shown that transcription and translation of the upstream ZivJ gene have a 
definite inhibitory effect on expression of the downstream ZivK gene. The magnitude of 
this inhibition is variable. In the X8605 strain background, no detectable leucine-specific 
binding protein is produced unless a rho lesion is introduced. This result may explain 
reports by other workers who have not observed leucine-specific uptake in certain E coli 
strains [32] . The significant levels of leucine-specific binding protein observed in our 
laboratory may be due to a high basal level of expression of the ZivK gene in our E coli 
strains. 
As shown by the data in Tables I1 and 111, the expression of ZivK may be further 
stimulated when the livJ gene is mutated or deleted. This result is observed whether ZivK 
is in the chromosome or carried on a plasmid. Several explanations for this phenomenon 
are possible, but the data presented in this paper suggest that the 500 base pair non-coding 
region directly in front of the ZivK gene may contain an independent promoter that 
ordinarily is inactive but that can be activated in response to mutations or other events 
that reduce ZivJ expression. Several lines of evidence suggest that this explanation is likely. 
First, it is clear from the results in Table V that the rho effect cannot be explained solely 
on the basis of increased read-through of the downstream ZivK since ZivJ is also affected. 
Thus it appears that rho can operate in regulatory regions preceding both the ZivJ and 
livK genes. Second, the expression of ZivK is either unaffected or slightly elevated on the 
POX1 : :tn5ZivJ24 plasmid, which contains the 5.5 kb tn5 transposon inserted in the ZivJ 
gene. It is unlikely that RNA polymerase, which initiates transcription at a promoter in 
front of IivJ, would successfully transcribe the entire tn5 sequence and continue through 
to the ZivK gene. While transcription of the ZivK gene might initiate at a promoter within 
the tn5 transposon, we consider it more probable that the ZivK gene has a separate pro- 
moter. Third, the expression of the ZivK gene on the p o x 7  plasmid is still regulated by 
L-leucine. The effect o f lhe  regulatory mutations ZivR and ZstR also support this inter- 
pretation. Anderson and co-workers have shown that lstR leads to a dramatic derepression 
of leucine-specific binding protein synthesis, whereas ZivR leads primarily to an increase in 
the LIV-binding protein [ 111 . Both of these lesions map at min 20 on the E coli linkage 
map. Since these mutations complement each other genetically, they appear t o  represent 
MTN: 351 
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independent negatively acting regulatory elements. The fact that they differentially affect 
l ivJ  and livK expression stongly suggests that the livR gene product acts as a promoter 
in front of livJ, and that the lstR gene product acts as promoter in front of ZivK. Finally, 
in support of a separate regulatory region for the livK gene, the 500 base pair AT-rich 
region, immediately upstream of the livK gene, contains the sequence TGTTTGTCTAT- 
CAATAAATTCGGAATATTATCTGTTC approximately 250 bases upstream from the 
ZivK start codon. This sequence corresponds closely to the conserved elements (underlined) 
or previously identified RNA polymerase promoters [ 3 3 ] .  
In developing a model for leucine transport regulation, the effects of leucyl-tRNA, 
rho factor, and ppGpp must be considered. With the exception of rho factor, we do not 
know whether the other regulatory elements alter the expression of only one, or both 
binding protein genes. In addition, the derepressing effects of mutations hisT and leuSl 
may be due either to negative regulation by leucyl-tRNA or to a positive effect of un- 
charged tRNAleU. 
Our present understanding of the regulation of high-affinity leucine transport is 
presented in Figure 3.  This is represented schematically as a working model, and is not 
intended to represent precisely the interactions of the various regulatory factors. We sug- 
gest that two regulatory loci are involved. The first, in front of the ZivJgene, ordinarily 
allows high-efficiency transcription of livJ. Regulation at the l i v J  promoter is accomplished 
by the 1ivR gene product, a negative effector for 1ivJ gene expression. In addition, trans- 
cription termination factor rho and tRNAleU also regulate l ivJ expression [ 101 . As shown 
in Figure 3, we suggest that a second regulatory site, most likely including a second 
promoter, exists directly in front of livK. The product of 1stR apparently acts at the livK 
promoter in a manner similar to the action of livR gene product at the l ivJ  promoter. 
Finally, we wish to point out the evolutionary implications of this model. On the 
basis of amino acid sequences obtained by Dr. Ovchinnikov and colleagues [34; personal 
communication] and our own DNA sequencing studies it is clear that livJ and livK have 
evolved from a common ancestral gene by gene duplication. The amino acid sequence of 
the two binding proteins is approximately 80% conserved. Regions X and Y show similar- 
- 
l i vR  - l s t R  -
/I-)\- (+) ; Y 
(-1 
ppGpp rho leucyl- t R N A Y  -3 t R N A y  + Leucine 
leuS1 
- I' - hisT 
t R N A  
Fig. 3. Model of leucine transport regulation in Escherichia coli. 
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ities in size and position, suggesting that this duplication involved a larger region than the 
binding protein gene itself. If the regulatory regions in front of livK and livJ were included 
in this duplication, then these regions have diverged from a common ancestor, since the 
two genes are now regulated differently. Additional sequence analysis will provide more 
information on the evolutionary relationships of the regulatory regions and mechanisms. 
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